← Back to Search

Radiation Therapy

Stereotactic Body Radiation Therapy for Renal Cell Carcinoma

N/A

Recruiting

Led By Stanley Liauw

Research Sponsored by University of Chicago

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 1 year

Awards & highlights

Study Summary

This trial is testing the side effects and best dose of a cancer radiation therapy that targets tumors directly.

Eligible Conditions

Renal Cell Carcinoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of radiation therapy (RT)-related grade >= 4 toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0

Secondary outcome measures

Progression-free survival, defined as progression in the treated lesion, organ in which the treated lesion is present, distant failure, or death from any cause

Toxicity profile of 5-fraction SBRT based on normal tissue dosimetric constraints based on the organ site of involvement

Treated lesion control (LeC), defined as absence of clinical or radiographic progression per Response Evaluation Criteria in Solid Tumors (RECIST)

Side effects data

From 2022 Phase 2 trial • 29 Patients • NCT02045446

79%

Cough

64%

Dyspnea

64%

Nausea

57%

Fatigue

43%

Constipation

36%

Pain

36%

Dizziness

29%

Anemia

29%

Back pain

29%

Vomiting

21%

Anorexia

21%

Chest pain

21%

Lymphocyte count decreased

21%

Death NOS

21%

Anxiety

21%

Fall

14%

Wheezing

14%

Dysphagia

14%

Hypotension

14%

Depression

14%

Diarrhea

14%

Platelet count decreased

14%

Abdominal Pain

14%

Edema

14%

Fever

14%

Headache

14%

Insomnia

14%

Palpitations

Otitis externa

Alopecia

Sinusitis

Dehydration

Dysgeusia

Hemorrhoids

Amnesia

Confusion

Hypertension

Hypernatremia

Creatinine increased

Dementia

Productive cough

Pneumonitis

Dysuria

White blood cell count decreased

Throat pain

Bone marrow biopsy

Blurred vision

Hearing impaired

Rash

Eye pain

Tachycardia

Lung infection

Neuropathy

Pleuritic pain

Neutropenia

Hypoxia

Aspiration pneumonia

Blood bilirubin increased

Muscle weakness

Tremor

Weight loss

Thrombocytopenia

Floaters

Toothache

Esophagitis

Leukocytosis

Edema limbs

Gait disturbance

Parathesia (tingling)

Edema face

COPD

100%

80%

60%

40%

20%

Study treatment Arm

Stereotactic Body Radiation Therapy

Maintenance Chemotherapy

Trial Design

1Treatment groups

Experimental Treatment

Group I: Stereotactic body radiation therapyExperimental Treatment1 Intervention

Patients undergo stereotactic body radiation therapy on day 1 over 3 times a week for 28 days in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Stereotactic Body Radiation Therapy

2012

Completed Phase 2

~780

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of ChicagoLead Sponsor

1,001 Previous Clinical Trials

817,705 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,933,128 Total Patients Enrolled

Stanley LiauwPrincipal InvestigatorUniversity of Chicago Comprehensive Cancer Center

1 Previous Clinical Trials

60 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any current openings in this experiment for participants?

"According to the clinicaltrials.gov, this medical trial is currently recruiting patients and was first announced on May 1st 2015 before being revised on June 3rd 2022."

Answered by AI

How many individuals can participate in this experiment?

"Affirmative, the particulars on clinicaltrials.gov confirm that this research endeavour is actively seeking candidates. The trial was first made public on May 1st 2015 and has since seen regular updates, with the most recent one taking place June 3rd 2022. 25 people are to be admitted at a single medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

2015. "Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02542202.

All > Kidney Cancer